| EN

Iremod®:Iguratimod tablets

Iremod®:Iguratimod tablets


Indications: Active rheumatoid arthritis.


Rheumatoid arthritis is a long-term systemic autoimmune disorder. Although there is no cure for rheumatoid arthritis, clinical studies have indicated that long-term and routine use of DMARDs at early stage of diseases can alleviate symptoms as well as postpone the progression of diseases.

Currently, pharmaceuticals for treatment of rheumatoid arthritis include conventional synthetic DMARDs, other DMARDs (mainly comprising biological DMARDs and targeted synthetic DMARDs), glucocorticoid and non-steroidal anti-inflammatory pharmaceuticals. Our Iremod® (iguratimod tablets) is the first iguratimod pharmaceutical product approved for sale in the world and the only iguratimod pharmaceutical product approved for sale in China. It is also the only PRC-developed small molecule DMARD that was launched in the past 10 years.

Iguratimod is recommended as the primary therapy drug for treatment of active rheumatoid arthritis by a number of clinical practice guidelines and pathways issued by the NHC, Chinese Medical Association, Asia Pacific League of Associations for Rheumatology and the Ministry of Health, Labor and Welfare of Japan.

Iguratimod has been included in the NRDL since 2017.